NeurAxon Focusing On Migraine With Aura For nNOS Inhibitor
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Based on a post-hoc analysis of a failed Phase II trial, NeurAxon will focus further development of the neuronal nitric oxide synthase inhibitor on the subset of migraine patients who experience aura